Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

EAU 2026: Updates in NMIBC

Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte
EAU 2026: Updates in NMIBC ( Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte )
18 Mar 2026

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands
Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )
18 Mar 2026

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer

Dr Jonathan Anker - Mount Sinai Hospital, New York, USA
Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer ( Dr Jonathan Anker - Mount Sinai Hospital, New York, USA )
18 Mar 2026

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival

Dr Nicholas Salgia - Roswell Park Comprehensive Cancer Center, Buffalo, USA
Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival ( Dr Nicholas Salgia - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
18 Mar 2026

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain
Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer ( Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain )
18 Mar 2026

Circulating tumour DNA shows high accuracy for monitoring testicular cancer across all stages

Dr Dalia Kaakour - University of California, Irvine, USA
Circulating tumour DNA shows high accuracy for monitoring testicular cancer across all stages ( Dr Dalia Kaakour - University of California, Irvine, USA )
18 Mar 2026

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer

Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA
Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer ( Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA )
18 Mar 2026

Belzutifan plus palbociclib shows modest activity with manageable safety in heavily pretreated kidney cancer

Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA
Belzutifan plus palbociclib shows modest activity with manageable safety in heavily pretreated kidney cancer ( Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )
18 Mar 2026

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer

Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA
Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer ( Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )
18 Mar 2026

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
18 Mar 2026

Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
18 Mar 2026

Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada
Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )
18 Mar 2026